Methods for reducing adverse side effects associated with cellular transplantation
Patent Number: 6387366
Date of First Priority Issue: Thursday December 31st, 1998
Date Issued: Tuesday May 14th, 2002
Assignee: ALG Company (Marlboro, MA)
Inventors: Hurwitz, David R. (Boston, MA); Cherington, Van (Harvard, MA); Galanopoulos, Theofanis (Arlington, MA); Levine, Peter H. (Worcester, MA); Greenberger, Joel S. (Sewickley, PA)
From Class: Use
Comments: No comments
This patent teaches ways how to overcome some of the negative effects associated with cell therapy in regards to excessive coagulation. It is stated in the specification that in many cases the administration of a cellular therapy results in coagulation of blood due to expression of pro-clotting agents on the surface of the administered blood cells such as tissue factor. The patent teaches ways of overcoming this by providing antibodies, antisense oligos, and proteins that can be used to prevent hypercoagulation.
View this patent on the USPTO website.
Added to StemCellPatents.com on Monday October 16th, 2006
Social & Bookmarking:
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.